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Background: The risk factors responsible for breast cancer have been well documented, but the roles of
risk factors as initiators, causing the occurrence of screen-detected breast cancer, or promoters,
responsible for the progression of the screen-detected to the clinically-detected breast cancer, have been
scarcely evaluated.
Methods: We used data from women in a cohort in Kopparberg (Dalarna), Sweden between 1977 and
2010. Conventional risk factors, breast density, and tumor-specific biomarkers are superimposed to the
temporal course of the natural history of the disease.
Results: The results show that older age at first full-term pregnancy, dense breast, and a family history of
breast cancer increased the risk of entering the preclinical screen-detectable phase of breast cancer by
23%, 41%, and 89%, respectively. Overweight/obesity (body mass index 25 kg/m2) was a significant
initiator (adjusted relative risk [aRR] 1.15; 95% confidence interval [CI], 0.99e1.33), but was inversely
associated with the role of promoter (aRR 0.65; 95% CI, 0.51e0.82). Dense breast (aRR 1.46; 95% CI, 1.12
e1.91), triple-negative (aRR 2.07; 95% CI, 1.37e3.15), and Ki-67 positivity (aRR 1.66; 95% CI, 1.19e2.30)
were statistically significant promoters. When the molecular biomarkers were considered collectively as
one classification, the basal-like subtype was the most influential subtype on promoters (aRR 4.24; 95%
CI, 2.56e7.02) compared with the Luminal A subtype.
Discussion: We ascertained state-dependent covariates of initiators and promoters to classify the risk of
the two-step progression of breast cancer. The results of the current study are useful for individually-
tailored screening and personalized clinical surveillance of patients with breast cancer that was detec-
ted at an early stage.
© 2016 The Authors. Publishing services by Elsevier B.V. on behalf of The Japan Epidemiological
Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).y and Preventive Medicine,
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Hormonal risk factors that are responsible for breast cancer have
been well documented since 1980.1,2 The majority of studies place
emphasis on whether or not breast cancer occurs. Mathematical
models that predict the risk of breast cancer, such as the Gail model,
have been proposed for such a purpose.3e7 In the era of preventive
medicine, a simple relationship of a particular risk factor to the
occurrence of breast cancer is not sufficient. Considering then Epidemiological Association. This is an open access article under the CC BY-NC-ND
Fig. 1. Breast tumors that remained in the PCDP and the CP, as represented by screen-detected and clinically-detected interval breast cancers in relation to initiators and promoters.
* The dashed line represents the unobserved status, while the solid line and underscored text represent the observed status. BC, breast cancer; CP, clinical phase; PCDP, pre-clinical
detectable phase.
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Fig. 1, women experience a pre-symptomatic phase before they
progress to the symptomatic phase. The majority of women are
initially free of breast cancer (case 1). In cases of breast cancer, the
tumor develops as a very small and pre-symptomatic lesion, which
is undetectable. As time passes, the tumors clone and grow to a
detectable size, and although womenmay still be pre-symptomatic
during this phase, the tumor can be detected using available
screening tools, such as mammography; even at this stage, women
may still not exhibit any symptoms and signs (the so-called pre-
clinical detectable phase [PCDP]). The PCDP is the window of early
detection. If the lesion is detected through screening during the
period when women are in the PCDP, they are defined as “screen-
detected cases” (case 2 and case 3). If women enter the PCDP after
screening but progress to a clinical phase after they feel lumps or
experience symptoms and signs (the clinical phase [CP]) and then
seek medical care, these are defined as “interval cancers” (case 4).
The risk factors of interest may be related to the rate of entering the
PCDP (initiators) and also may be responsible for the subsequent
progression from the PCDP to the CP (promoters). The elucidation
of the function of each risk factor with respect to its role as an
initiator or a promoter is of great importance to individually-
tailored screening and personalized clinical surveillance.
However, the classification of each risk factor as an initiator or a
promoter is a great challenge unless the data from a population-based breast cancer screening are considered. These data provide
an opportunity to assess the relative contribution between initia-
tors and promoters through a comparison of the distribution of
each risk factor between screen-detected breast cancers (pre-
symptomatic cases that remained in the PCDP) and clinically-
detected breast cancers. An example of clinically-detected breast
cancer is interval cancer, which represents progression of cancer
from the PCDP that was already found at a previous screen and was
missed or that progressed to the CP after the screen but before
subsequent screening (i.e., symptomatic cases). In addition to the
conventional hormonal risk factors, information on the status of
estrogen receptor (ER), progesterone receptor (PR), HER-2/neu, and
Ki-67, as well as the presence of a basal-like phenotype, are widely
used to predict the prognosis of breast cancer; these additional
factors are also very informative with respect to the rate of pro-
gression from the pre-symptomatic phase to the symptomatic
phase.8e10 Because only breast tumor cases have such information,
it is postulated that if the distributions of these factors are different
between screen-detected and clinically-detected interval cancers,
these tumor-specific markers might play a crucial role as
promoters.
In the current study, we aimed to use longitudinal follow-up
data from Kopparberg (Dalarna) county in the Swedish two-
county trial of mammography screening. We applied a four-state
continuous-time Markov regression model to estimate the
A.M.-F. Yen et al. / Journal of Epidemiology 27 (2017) 98e106100incidence rate of preclinical breast cancer based on screen-detected
breast cancers and the transition rate from the PCDP to the CP based
on interval breast cancers, taking into account the hazard rate of
dying from causes other than breast cancer. We also estimated the
relative risks (RRs) of the associated risk factors on the two rates
governing the disease progression described above.
2. Methods
2.1. Study subjects
Subjects were enrolled from one county of the Swedish two-
county trial in Kopparberg (Dalarna), with a follow-up period
from 1977 until 2010. The details of the trial have been described in
full elsewhere.11 Briefly, women aged 40e74 years in the screening
armwere invited to participate in screenings every 24e33 months.
At the close of the trial (1985), the service screening with two-view
mammography screening was recommended by the Swedish Board
of Health and Welfare for women aged 40e69 years. Data on the
individual screening history of patients, including negative find-
ings, breast cancers detected during screens, and those cases that
were diagnosed between the scheduled screens due to the occur-
rence of symptoms and signs, were collected and followed until
1992. Data on breast cancer cases from 1993 to 2010 from the
cancer registry (which is the most common scenario in the real
world) were used. Data on date and causes of death for all breast
cancer patients were obtained from the death registry. The number
of disease-free women after 1992 was approximated based on the
population statistics in Sweden (http://www.scb.se). The average
inter-screening interval after 1992 was 24 months. To estimate the
hazard rate of competing causes of death other than breast cancer,
frequencies of death of the underlying population by age and cal-
endar year were retrieved from the population statistics in Sweden.
2.2. Study design
In all, 50,666women aged 40e74 years at the beginning of study
were identified. As conventional risk factors were not collected
after 1992, and because tumor-specific factors were also collected
in different calendar years after 1992, we divided the follow-up
time into two eras: 1977e1992 and 1993e2010. The record of the
participants in each screenwas kept until 1992, as were data on the
date of mammography, the screening results, andwhether a clinical
diagnosis was made after negative findings. In the current analysis,
we did not include thosewho had never attended a screen but were
diagnosed with clinically-detected breast cancer due to the pres-
ence of symptoms and signs (those who refused mammography).
They were excluded because information on conventional risk
factors was not available for the women who refused to attend the
screen. Within the analytic cohort, we further distinguished each
woman as breast cancer-free, as a case of screen-detected breast
cancer (in the PCDP), or as a case of interval cancer (in the CP).
During this period, 1321 breast cancers were identified, including
789 screen-detected and 532 interval cancers. Between 1993 and
2010, 1614 breast cancers (1135 screen-detected and 469 interval
cancers) were diagnosed in women aged 40e69 years and were
reported in the cancer registry. As mentioned earlier, the number of
disease-free women at each round of screening after 1992 was
approximated from the population statistics. A flowchart of the
screening and the corresponding data is shown in Fig. 2. In the
current analysis of four-stateMarkovmodel, the layout of data used
for analysis is displayed in eTable 1, including vital status on death
from causes other than breast cancer and for women free of breast
cancer by 1-year age retrieved from the Swedish population sta-
tistics. Data onwomen-years of follow-up by 1-year age for womenin the PCDP and those free of breast cancer are also given in
eTable 1.
2.3. Data collection
2.3.1. Conventional risk factors
In the trial period, the screening staff took anthropometric
measurements for each woman at the first screening. We used a
body mass index (BMI) of 25 kg/m2 to categorize women as over-
weight/obese (BMI 25 kg/m2) or not (BMI <25 kg/m2). A ques-
tionnaire was also used to obtain information on the age at
menarche, menopausal status, age at first full-term pregnancy (AP),
and family history of breast cancer.
2.3.2. Breast density
All mammographs were performed by well-trained technicians
from Falun Central Hospital following a standard procedure.12
Women at the inception of the trial were classified with either
baseline dense breast (Tabar patterns IV and V) or non-dense breast
(Tabar patterns I-III).13 Note that Tabar patterns IV and V corre-
spond to Wolfe patterns P2 and DY, excluding QDY.14
2.3.3. Tumor-specific biomarkers
All tumor-specific biomarkers were examined in the Depart-
ment of Pathology, Falun Central Hospital starting in 1996. Bio-
markers included ER, PR, HER-2, Ki-67, and basal/myoepithelial
markers, but different biomarkers were available in different years
depending on the hospital policy (see Fig. 2). Tumors that
expressed at least one of the basal/myoepithelial markers,
including cytokeratin (CK)5/6, CK14 and Epidermal Growth Factor
Receptor, were classified as tumors with a basal-like phenotype.
Immunohistochemistry-based molecular analysis allowed for
further categorization into five molecular subtypes: Luminal A
(ERþ, PRþ/, HER-2), Luminal B (ERþ, PRþ/, HER-2þ), HER-2-
like (ER, PR, HER-2þ), basal-like subtype (positive for at least
one basal/myoepithelial marker) and triple-negative (ER, PR,
HER-2).15 Note that because we treated the basal-like subtype as
the dominate subtype, this subtype also included tumors with a
basal-like phenotype. The other four molecular subtypes collec-
tively included tumors without a basal-like phenotype. The data
used for academic purposes have been approved by the Regional
Ethics Committee in Uppsala, €Orebro, Sweden (Dnr 2008/081).
2.3.4. Statistical analysis
We applied a four-state continuous-time Markov model to
delineate the disease progression of breast cancer from the breast
cancer-free phase (state 0), to the PCDP (state 1), and finally, to the
CP (state 2), making allowance for deaths due to causes other than
breast cancer (state 3) fromwomen with states 0 and 1 (see Fig. 3).
Both states 2 and 3 are viewed as absorbing states, as the CP is the
destination of the natural history of breast cancer and women free
of breast cancer and in the PCDP may die from causes other than
breast cancer. The methods of the multi-state Markov model have
been well developed and have been previously applied to breast
cancer screens.16e20 The two instantaneous transition rates that
govern the disease progression of breast cancer are denoted by l1
and l2 (Fig. 3). The mean sojourn time (MST) is equal to 1/l2 under
the exponential assumption. The hazard rates of other causes of
death from states 0 and 1 are denoted by m0 and m1, respectively.
This four-state model was further used to model the effect of
covariates on different transitions. The log-linear hazards regres-
sion form was used to relate covariates to the incidence of breast
cancer (transition rate from the breast cancer-free phase to the
PCDP) and the transition from the PCDP to the CP.10 The details of
the statistical model are given in eAppendix 1. Those factors that
Fig. 2. The flowchart of the screen and data collection according to study period. SD, screen detected case; IN, interval case.
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initiators, and those that were responsible for the progression from
the PCDP to the CP were classified as promoters. We first consid-
ered the effect of single covariate simultaneously on l1 and l2 in the
proposed four-state model. The model considering multiple cova-
riates with forward selection was further applied. Statistical com-
parisons were two-sided, and a p-value of less than 0.05 was
considered statistically significant.3. Results
Women who were overweight/obese (BMI 25 kg/m2), those
with an early age at menarche, those with a late AP, and womenwith a family history of breast cancer were more likely to enter the
PCDP (eTable 2). However, the association was statistically signifi-
cant (P < 0.05) only for the last two factors. Comparing screen-
detected cases and interval cases, only overweight/obesity was
statistically significant (P ¼ 0.005). eTable 2 also shows the distri-
butions of molecular markers in cases of breast cancer. ER and PR
negativity, HER-2 and Ki-67 positivity, triple-negative status, and a
basal-like phenotype were more frequently observed in clinically-
detected breast cancers than in screen-detected breast cancers
(P < 0.05).
With the application of a four-state continuous-time Markov
model as shown in Fig. 3, the estimated annual incidence of PCDP
breast cancer was 2.0 (95% CI, 1.97e2.12) per 1000 persons. The
Fig. 3. The four-state Markov model for disease progression of breast cancer. BC, breast cancer; CP, clinical phase; OCD: other cause of death; PCDP, pre-clinical detectable phase. l1:
the rate of entering the PCDP that would be affected by initiators l2: the progression rate from the PCDP to the CP that would be affected by promoters. mi: the death rates due to
causes other than breast cancer from State i (i ¼ 0, 1).
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0.36e0.41), yielding 2.62 years (95% CI, 2.46e2.80) of MST. The
death rates from other causes were 0.0062 (95% CI, 0.0061e0.0064)
for women free of breast cancer (State 0), and 0.0116 (95% CI,
0.0100e0.0133) for breast cancer in the PCDP.
This model was further extended to an exponential regression
Markov model to investigate the joint effects of the roles of each
factor in terms of initiators and promoters (Table 1). The results
show that, as an initiator, late AP led to a significant 23% increased
risk (RR 1.23; 95% CI,1.10e1.39) of entering the PCDP; as a promoter,
the 15% decreased risk was not statistically significant (RR 0.85; 95%
CI, 0.71e1.03). BMI 25 kg/m2 led to a statistically significant 42%
decrease in the risk of breast cancer in terms of its role as a pro-
moter (RR 0.58; 95% CI, 0.46e0.73) but had a marginally significant
10% elevated risk in its role as an initiator (RR 1.10; 95% CI,
0.95e1.27). Compared with non-dense breast tissue, dense breast
tissue was associated with significantly increased risks of 21% (RR
1.21; 95% CI, 1.02e1.44) as an initiator and 78% (RR 1.78; 95% CI,
1.37e2.32) as a promoter. Family history also played a role as an
initiator (RR 1.88; 95% CI, 1.34e2.64), but not as a promoter (RR
0.83; 95% CI, 0.50e1.38).Table 1
The results of relative risks for risk factors as initiators and promoters when c
Markov model.
Risk factors
Age at menarche, 12 years vs. 11 years
Age at first full-term pregnancy, 25 years vs. >25 years
BMI, 25 kg/m2 vs. <25 kg/m2
Breast density, Dense vs. Non-dense
Family history, Yes vs. No
ER, Neg. vs. Pos.
PR, Neg. vs. Pos.
HER-2, Pos. vs. Neg.
Triple-negative, Yes vs. No
Ki-67, Neg. vs. Pos.







BMI, body mass index; CI, confidence interval; NA, not applicable; RR, relativ
RR1: Relative risk for initiators as it relates to the risk of the development of
RR2: Relative risk for promoters as it relates to the risk of progression from tTable 1 also shows the RR of molecular biomarkers as they
related to promoters. The most notable biomarker was basal-like
phenotype (RR 3.85; 95% CI, 2.34e6.31), followed by triple-
negative status (RR 3.28; 95% CI, 2.28e4.70). Other significant risk
factors that acted as promoters included ER negativity (RR 2.55;
95% CI, 1.95e3.33), PR negativity (RR 1.74; 95% CI, 1.39e2.18), HER-2
positivity (RR 1.54; 95% CI, 1.09e2.18), and Ki-67 positivity (RR 2.36;
95% CI, 1.69e3.29). When these biomarkers were reclassified into
different molecular subtypes, we found that compared with
Luminal A, the basal-like subtype was the most significant risk
subtype for the promotion of disease progression (RR 4.24; 95% CI,
2.56e7.01).
The adjustment of multiple covariates for each other, as shown
in Table 2, demonstrates that late AP, dense breasts, and a family
history of breast cancer enhance the risk of entering the PCDP by
23% (95% CI, 10%e38%), 41% (95% CI, 19%e68%), and 89% (95% CI,
36%e163%), respectively (Table 2). It is interesting that overweight/
obesity may act as an initiator (adjusted RR [aRR] 1.15; 95% CI,
0.99e1.33) but was inversely associated with the risk of acting as a
promoter (aRR 0.65; 95% CI, 0.51e0.82). Dense breasts (aRR 1.46;
95% CI, 1.12e1.91), triple-negative status (aRR 2.07; 95% CI,
1.37e3.15), and Ki-67 positivity (aRR 1.66; 95% CI, 1.19e2.30) wereonsidered independently in the continuous-time exponential regression
Initiators Promoters
RR1 (95% CI) RR2 (95% CI)
0.84 (0.58, 1.20) 1.06 (0.57, 1.95)
1.23 (1.10, 1.39) 0.85 (0.71, 1.03)
1.10 (0.95, 1.27) 0.58 (0.46, 0.73)
1.21 (1.02, 1.44) 1.78 (1.37, 2.32)
1.88 (1.34, 2.64) 0.83 (0.50, 1.38)
NA 2.55 (1.95, 3.33)
NA 1.74 (1.39, 2.18)
NA 1.54 (1.09, 2.18)
NA 3.28 (2.28, 4.70)
NA 2.36 (1.69, 3.29)
NA 3.85 (2.34, 6.31)
NA 1.00
NA 1.74 (0.99, 3.05)
NA 1.51 (0.69, 3.28)
NA 4.24 (2.56, 7.01)
NA 2.06 (0.75, 5.69)
e risk.
breast cancer.
he PCDP to the CP.
Table 2
The results of relative risks for risk factors as initiators and promoters when considered jointly in the continuous-time exponential regression
Markov model.
Parameters Model 1 Model 2
aRR (95% CI) aRR (95% CI)
Initiators
BMI, 25 vs. <25 kg/m2 1.15 (0.99, 1.33) 1.15 (0.99, 1.34)
Age at first full-term pregnancy, >25 y vs. 25 y 1.23 (1.10, 1.38) 1.23 (1.10, 1.38)
Breast density, Dense vs. Non-dense 1.41 (1.19, 1.69) 1.41 (1.19, 1.68)
Family history, Yes vs. No 1.89 (1.36, 2.63) 1.89 (1.36, 2.63)
Promoters
BMI, 25 vs. <25 kg/m2 0.65 (0.51, 0.82) 0.65 (0.52, 0.81)
Breast density, Dense vs. Non-dense 1.46 (1.12, 1.91) 1.46 (1.13, 1.89)
Triple-negative, Yes vs. No 2.07 (1.37, 3.15) NA
Ki-67 expression, Pos. vs. Neg. 1.66 (1.19, 2.30) NA
Basal-like phenotype, Yes vs. No 1.71 (0.95, 3.10) NA
Molecular subtype
Luminal A NA 1.00
Luminal B NA 1.74 (0.99, 3.04)
HER-2þ NA 1.51 (0.70, 3.26)
Basal-like subtype NA 4.24 (2.56, 7.02)
Triple-negative NA 2.06 (0.75, 5.69)
aRR, adjusted relative risk; BMI, body mass index; CI, confidence interval; NA, not applicable.
Model 1: The effects of biomarkers were treated as independent.
Model 2: The combination of the status of ER, PR, HER-2 and basal-like phenotype was used to classify the cancer into 5 subtypes.
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each other. The role of a basal-like phenotype after adjustment for
these factors was only marginally significant. When the molecular
biomarkers were considered collectively as one classification
(Model 2), the basal-like subtype was the most influential subtype
that acted as a promoter (aRR 4.24; 95% CI, 2.56e7.02) compared
with Luminal A. The Luminal B, HER-2-positive, and triple-negative
subtypes had similar estimated results as shown in Table 1.
The estimated incidence of preclinical breast cancer ðbl1Þ, the
transition rate from the PCDP to the CP ðbl2Þ, and the estimated
MSTs of all possible risk profiles based on the combination of five
covariates (80 subgroups) are provided in eTable 3. The rate of
entering the PCDP ranges from the lowest (0.001) for womenwith a
BMI <25 kg/m2, early AP, non-dense breasts, and for those without
a family history of breast cancer to the highest (0.0036) for the
opposite characteristics (BMI25 kg/m2, late AP, dense breasts, and
a family history of breast cancer). Given the postulate that a shorter
MST and a higher preclinical incidence rate imply a higher risk for
the progression of breast cancer, we used the ratio of theMST to the
preclinical incidence rate (M/IPCDP) as a surrogate indicator for risk
stratification. The lower the M/IPCDP is, the higher the risk. If the
first (Q1 ¼ 603) and third quartiles (Q3 ¼ 1695) of M/IPCDP are
considered the cut-off points, we defined thosewith anM/IPCDP less
than Q1 as high risk, those with an M/IPCDP larger than Q3 as low
risk, and those with an M/IPCDP between Q1 and Q3 as intermediate
risk.
Fig. 4 shows the transition probabilities of the different char-
acteristics of three subjects who each represent different risk
groups.
Subject A: BMI25 kg/m2, AP > 25, dense breasts, family history
of breast cancer, basal-like subtype (High risk, bl1 ¼ 0:0036,
MST ¼ 0.86 years, M/IPCDP ¼ 237).
Subject B: BMI <25 kg/m2, AP > 25, dense breasts, no family
history of breast cancer, HER-2þ molecular subtype (Interme-
diate risk, bl1 ¼ 0:0022, MST ¼ 2.28 years, M/IPCDP ¼ 1022).
Subject C: BMI<25 kg/m2, AP 25, non-dense breasts, no family
history of breast cancer, Luminal A molecular subtype (Low risk,
bl1 ¼ 0:0010, MST ¼ 3.44 years, M/IPCDP ¼ 3597).The 2-year transition probabilities from “breast cancer-free” to
the CP decreased from 0.44% for Subject A to 0.05% for Subject C.
Fig. 4a and b show dynamic curves that indicate the evolution of
breast cancer from “breast cancer-free” through the PCDP and
finally to the CP following the temporal course of the natural his-
tory of breast cancer. A higher-risk subject, such as Subject A, had
higher odds of progression from the PCDP to the CP (Fig. 4c), which
led to a lower chance of entering the PCDP (Fig. 4b) following a
fixed cohort study after 10 years of follow-up.4. Discussion
We used cases of screen-detected breast cancer and cases of
clinically-detected interval breast cancer obtained from a longitu-
dinal breast cancer study in Sweden, in conjunction with a four-
state continuous-time exponential regression Markov model, to
assess the role of each risk factor played in both the initiation and
the progression of breast cancer. We found that BMI, AP, breast
density, and family history of breast cancer are regarded as initia-
tors, while BMI, breast density, triple-negative status, Ki-67
expression, and basal-like phenotype or molecular subtypes are
promoters. This method was very useful for the investigation of the
impact of these risk factors on the occurrence of breast cancer
(entering the PCDP), and also on the MST, which is the average time
of progression from the PCDP to the CP.
BMI is a well-known risk factor for breast cancer: one meta-
analysis reported that the risk ratio for breast cancer was 1.12
(95% CI, 1.08e1.16) for each 5 kg/m2 increment.21 In our study, the
hazard ratio for the incidence of preclinical breast cancer for
women with a BMI greater than 25 kg/m2 was equal to 1.15 when
other risk factors were taken into account. Furthermore, the haz-
ard ratio for the transition from the PCDP to the CP for women
with a BMI greater than 25 kg/m2 was 0.65, which implies a
slower transition toward the CP (analogous to a longer mean
sojourn time in the PCDP) than women with a BMI less than 25 kg/
m2. The study by Kricker also found that a low BMI was highly
correlated with clinically-detected cancers.22 Subjects with a
higher BMI had a higher risk of developing breast cancer, but the
progression rate to the CP was relatively slow; this implies that
those subjects can be easily identified in the screening program.
Fig. 4. The illustration of the cumulative probabilities by time of three hypothetical subjects in different risk groups from high risk (Subject A) to low risk (Subject C).
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menopause, and number of live births, are believed to exert pro-
tective effects due to the hormonal changes during pregnancy and
lactation.23 We did not find any significant reduction in risk in
women with an older age at menarche in our study cohort, but
women with an AP greater than 25 years had a higher risk of
entering the PCDP. However, this factor did not act as a promoter.
Moreover, the radiographic appearance of the breast was a
consistent and strong risk factor for breast cancer.24 The study by
Chiu first described how to quantify the role of breast density on
the preclinical incidence rate and the MST.25 Based on the multi-
state model, the hazard ratio of the transition from “breast cancer-
free” to the PCDP for women with dense versus non-dense breasts
was 1.65, and that of the transition from the PCDP to the CP was
1.61; however, both estimates did not account for the adjustment
of other covariates. After adjustments for BMI, AP, family history,
and molecular type, the hazard ratios for dense breasts were 1.41
for the transition from “breast cancer-free” to the PCDP and 1.46
for the transition from the PCDP to the CP. The molecular subtypes
of breast cancer play important roles in the prediction of the
prognosis and are also considered when treatment modalities are
chosen. The different molecular subtypes reflect various biologic
characteristics of breast cancer tumors. Women with a shorter
sojourn time may have the poorest survival. However, studies that
have considered the MST according to different molecular types
are lacking. Our estimate of the hazard ratio of the transition ratefrom the PCDP to the CP corresponded to the estimate of the MST,
of which the mean value was the inverse of the transition rate
from the PCDP to the CP. A risk factor that acted as a promoter had
a shorter MST. We found that the shortest MST was associated
with a basal-like subtype, which is consistent with the finding that
patients with basal-like breast cancer experience poorer survival.8
Furthermore, a shorter MST indicates a smaller chance that the
cancer will be detected by screening. In our study, 18% of interval
cancers were the basal-like phenotype, whereas only 5% of screen-
detected cases showed the basal-like phenotype.
The results of the current study can serve as a predictive model
for the incidence of preclinical breast cancer and to determine the
likelihood that preclinical breast cancer will transition to the CP.
Predictive modeling of breast cancer has had a long history since
1983. The first was Pike's model, which predicted the risk of breast
cancer with the evolution of hormonal risk factors, including age at
menarche, AP, and age at menopause, together with weight.1 The
subsequent seminar work on the predictive model from Gail's
study was developed to integrate these hormonal risk factors.3
Several revisions and extensions, including the addition of post-
menopausal hormone levels (such as those of estrogen), body
weight, and alcohol consumption, were proposed by Colditz et al.26
Another addition includes a consideration of breast density (Barlow
et al.4 introduced genetic markers from the Claus model27 and
estimated the carrier probability of a BRCA 1/2 mutation from
Couch et al. and Parmingiani et al.28,29). Despite this abundance of
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cancer according to the preclinical and clinical phases, which has
become essential due to the current worldwide popularity of
screening. Nevertheless, the previous models suggest that, in our
model, we can further treat genetic markers as initiators when the
data become available.
4.1. Methodological consideration
In the current study, we investigated the joint effects of risk
factors for initiators and promoters using a time-continuous four-
state Markov model, which is different from the conventional
methods. Using conventional analysis methods, we identified risk
factors through a comparison of the distribution of risk factors
between women free of breast cancer and women with breast
cancer (for initiators). We also compared the distribution between
screen-detected and interval cancers (for promoters), as shown in
eTable 2. Although this is intuitive and the data are easy to access,
such a method could only be used to conduct an initial exploration
due to several shortcomings. First, for initiators, we had to compare
women free of breast cancer with those who had been diagnosed
with breast cancer, regardless of whether a particular woman had
screen-detected breast cancer or interval breast cancer. However,
the inclusion of interval cancer means that we have not only
introduced the influence of disease occurrence but also the tran-
sition from the PCDP to the CP. The two entangled forces of interval
cancers precluded the declaration that such a comparison was
purely for initiators. Second, the conventional means by which two
separate/independent comparisons are made could not capture the
covariance between two transitions (from “breast cancer-free” to
the PCDP and from the PCDP to the CP) and their regression co-
efficients. However, the biased standard error would affect the
inference of statistical significance. Third, the conventional method
failed to provide absolute estimates of the incidence and the MST
via the risk profiles, which is important for individually tailored
screening and also for surveillance programs.
Our four-state continuous-time exponential regression Markov
model enabled us to investigate the effects of risk factors on the
transition from “breast cancer-free” to the PCDP (initiators) and
from the PCDP to the CP (promoters) using data on screen-detected
and clinically-detected interval breast cancer. Although many
studies have investigated the risk factors of breast cancer by con-
ventional survival analysis, such as the Cox proportional hazards
regression model, these methods can only identify stage-specific
covariates with two separate models instead of the correlated
transitions of two states between “free of breast cancer” and the
PCDP and also between the PCDP and the CP. Moreover, even the
two separate models with the conventional survival analysis
required an explicit definition in terms of the start and end time to
an event, which was impossible to observe for the transition from
the PCDP to the CP in our case, as the PCDP is expressed as a screen-
detected case. The further transition from the PCDP to the CP would
be interrupted by medical intervention. With the Markov model,
we were able to estimate this hidden transition rate because it was
embedded in the second transition following the first transition
from “free of breast cancer” to the PCDP among those with interval
cancers.
4.2. Clinical implication
The elucidation of the respective contributions from relevant
factors is valuable for the prevention of breast cancer. From a
practical aspect, the identification of initiators can help in the
design of individually tailored prevention programs, and the
elucidation of promoters may enable us to consider individuallytailored surveillance strategies. The logarithm of the transition rate
from “breast cancer-free” to the PCDP can be taken as a risk score,
which allows us to stratify the population into different risk cate-
gories for individualized prevention programs. Information on in-
dividual breast cancer risk (initiator) may be tailored to offer
preventive interventions, such as diet, exercise, and hormonal
therapy. For secondary prevention, women at a higher risk would
be recommended to undergo screening at an earlier age.30 Infor-
mation on the MST can help to provide a shorter screening interval
or a more intensive surveillance strategy for those with a higher
risk (more promoters) to reduce false-negative and false-positive
cases. Furthermore, factors that are unknown during screening,
such as the molecular subtype, can be used to design individualized
surveillance regimes for women once they have been diagnosed
with cancer because the transition from the PCDP to the CP is an
indicator of tumor aggression.
The ratio of MST to preclinical incidence rate (M/IPCDP) can be
used as an indicator of whether it is economical to screen women
with a given risk based on the criteria that the optimal value would
be ideal for a specific screening policy under consideration. The
lower the M/IPCDP, the more cost-effective it will be to screen
women with a given risk. The values range from 176 to 4832. The
median value is approximately 1,004, which represents the women
with an average risk. If a triennial screening policy is applied to the
women with an average risk, it is clear that a value greater than
3000 would not be cost-effective if the screening policy was based
on an average-risk group. A screening program with a longer in-
terval, such as 8 years, and less aggressive adjuvant therapy would
be suggested. If the value was less than 500, the screening of such
high-risk women would be very cost-effective if an annual
screening program is chosen and more aggressive therapy is
applied.
We ascertained state-dependent covariates of initiators and
promoters to classify the risk of the two-step progression of breast
cancer. The application of such a risk assessment model to the
temporal and natural course of breast cancer contributes to
population-based risk stratification of patients with breast cancer
and also to our understanding of the subsequent progression to
advanced breast cancer. Such information is very helpful for indi-
vidually tailored screening programs and for personalized clinical
surveillance of early-detected breast cancer.
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